Abstract:p53 deficiency is common in almost all human tumors and contributes to an aggressive chemo- or radiotherapy-resistant phenotype, therefore providing a target for drug development. Molecular targeting to restore wild-type p53 activity has been attempted in drug development and has led to the identification of CP-311398, PRIMA1, and the Nutlins. However, strategies targeting p53-activated transcriptional responses or p53 family member expression in p53-deficient tumors have yet to be explored. Here we demonstrate the use of noninvasive bioluminescence imaging in a high-throughput cell-based screen of small molecules that activate p53 responses and cell death in human tumor cells carrying a mutant p53. We isolated a number of small molecules that activate p53 reporter activity, increase expression of p53 target genes such as p21(WAF1) or death receptor 5 (KILLER/DR5) of TNF-related apoptosis-inducing ligand (TRAIL), and induce apoptosis in p53-deficient cells. Some of the compounds activate a p53 response by increasing p73 expression, and knockdown of transactivating isoforms of p73 by small interfering RNA reduces their induction of p53-responsive transcriptional activity. Some compounds do not induce significant p73 expression but induce a high p53-responsive transcriptional activity in the absence of p53. In vivo experiments demonstrate potent antitumor effects of selected compounds, using either HCT116/p53(-/-) or DLD1 human colon tumor xenografts. The results establish the feasibility of a cell-based drug screening strategy targeting the p53 transcription factor family of importance in human cancer and provide lead compounds for further development in cancer therapy.

A novel facet of tumor suppression by p53: Induction of tumor immunogenicity.

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Current strategies to target p53 in cancer.

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Therapeutic targeting of p53 by small molecules

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity

Activating p53 with a Mutant-Specific Small Molecule

Targeting P53 for Novel Anticancer Therapy.

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis

A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors

190 Novel Classes of P53 Activators for Cancer Therapy

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Anticancer therapeutic strategies for targeting mutant p53-Y220C

Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?

How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?

Targeting mutant p53 for efficient cancer therapy